Systematic Analysis of STAT6 Protein: Domain Composition, Activation Cascade, and Disease Associations
Author: Senior Product Manager of UA Views：11 
This article systematically elaborates on the domain organization and activation mechanisms of signal transducer and activator of transcription 6 (STAT6), detailing the complete signaling cascade from cytokine receptor binding to JAK kinase phosphorylation, SH2 domain docking, dimerization, and nuclear translocation. It analyzes its immune functions in Th2 cell differentiation, B cell antibody class switching, and macrophage activation, as well as its role in cell differentiation and development, and explores its complex associations between abnormal activation and allergic diseases, autoimmune diseases, and tumors.
- Recent Advances
- Product Information
Recent Advances
STAT6 Protein: A Systematic Analysis of Domain Organization, Activation Cascade, and Disease Associations
Brief Introduction: This article focuses on the domain organization and activation mechanisms of signal transducer and activator of transcription 6 (STAT6), systematically describing the complete signaling cascade from cytokine receptor binding to JAK kinase phosphorylation, SH2 domain docking, dimerization, and nuclear translocation. It analyzes its immune functions in Th2 cell differentiation, B cell antibody class switching, and macrophage activation, as well as its role in cell differentiation and development, and discusses the complex associations between its aberrant activation and allergic diseases, autoimmune diseases, and tumors.
I. Domain Organization and Functional Module Division of STAT6.
The STAT6 protein is composed of multiple domains, including an N-terminal inhibitory domain, a DNA-binding domain, an SH2 domain, and a C-terminal transactivation domain. This four-module architecture of “inhibitory domain—DNA-binding domain—SH2 domain—transactivation domain” endows STAT6 with multiple functions: the N-terminal inhibitory domain participates in regulating the strength of its transcriptional activity and affects the stability of dimers; the DNA-binding domain determines the specificity of the target gene promoter sequences it can recognize; the SH2 domain undertakes the dual functions of receptor docking and intermolecular dimerization; and the C-terminal transactivation domain is responsible for recruiting transcriptional coactivators and initiating target gene expression. The division of labor and cooperation among these domains enable STAT6 to complete the entire functional chain from signal reception to transcriptional output within a relatively compact protein molecule.
II. Activation Cascade and Nuclear Translocation Mechanism of STAT6.
The activation process of STAT6 begins with the activation of cell surface receptors. For example, after IL-4 and IL-13 bind to their receptors, they activate receptor-associated tyrosine kinases such as JAK1 and JAK3. These kinases phosphorylate specific tyrosine residues of the receptor, providing docking sites for STAT6 binding. STAT6 recognizes and binds to the phosphorylated tyrosines on the receptor through its SH2 domain, and subsequently undergoes tyrosine phosphorylation itself. Phosphorylated STAT6 dimerizes to form homodimers or heterodimers and translocates into the nucleus, where it binds to specific DNA sequences and regulates the transcription of target genes. The core logic of this cascade lies in the three-step mechanism of “phosphorylated tyrosine as a docking signal, SH2 domain as a recognition module, and dimerization as a prerequisite for nuclear translocation,” in which the SH2 domain is both the key to receptor recognition and the structural basis for dimerization, thus becoming the hub region for functional regulation of STAT6.
III. Physiological Functions of STAT6 in the Immune System.
STAT6 mainly participates in the differentiation and functional regulation of Th2 cells in immune responses. IL-4 and IL-13 promote the development of Th2 cells by activating STAT6, causing them to secrete various cytokines such as IL-5, IL-10, and IL-13, which play important roles in humoral immunity, allergic reactions, and immunity against parasitic infections. For example, IL-5 can promote B cell proliferation and antibody secretion, and IL-10 has immunomodulatory effects and can inhibit Th1 cell-mediated cellular immune responses, maintaining immune balance. In addition, STAT6 also participates in regulating B cell proliferation, differentiation, and antibody class switching, as well as macrophage activation and function, affecting their performance in inflammatory responses. From the perspective of cell type division of labor, STAT6 directs Th2 lineage commitment in T cells, drives antibody class switching in B cells, and regulates activation phenotypes in macrophages; together, these three constitute the cytological basis of type 2 immune responses.
IV. Role of STAT6 in Cell Differentiation and Development.
In various cell types, STAT6 participates in the regulation of cell differentiation and development. For example, in epithelial cells, STAT6 affects intercellular adhesion and migration by regulating the expression of cell adhesion molecules, thereby participating in tissue formation and repair. During the differentiation of hematopoietic stem cells, STAT6 activity also plays a key role in the development of certain cell lineages, such as regulating erythropoiesis and megakaryocyte development. These findings suggest that the functions of STAT6 are not limited to the immune system; it also plays regulatory roles in the differentiation of non-immune cells and tissue formation, providing an evidence base for its role in broader physiological processes.
V. Associations of STAT6 with Diseases.
In terms of allergic diseases, because of the key role of STAT6 in Th2 cell differentiation and function, its aberrant activation is closely related to the occurrence of allergic diseases. In allergic asthma, overactivated STAT6 leads to a dominant Th2 cell response, producing large amounts of IgE antibodies and causing airway hyperresponsiveness and inflammatory cell infiltration. In addition, diseases such as allergic rhinitis and atopic dermatitis are also associated with STAT6-mediated dysregulation of Th2-type immune responses. Inhibiting STAT6 activity or blocking its signaling pathway is expected to become a new strategy for treating allergic diseases.
In terms of autoimmune diseases, dysfunction of STAT6 may lead to immune regulatory imbalance in certain autoimmune diseases. For example, in patients with systemic lupus erythematosus, abnormal activation of the STAT6 signaling pathway may be related to excessive B cell activation and the production of autoantibodies. However, the specific mechanisms of STAT6 in different autoimmune diseases may differ, and further research is needed to clarify its specific role in disease occurrence and development.
In terms of tumors, the role of STAT6 in tumor occurrence and development is relatively complex. On the one hand, aberrant activation of STAT6 may promote the proliferation and survival of certain tumor cells; for example, in some leukemia cells, sustained activation of the STAT6 signaling pathway helps tumor cells evade apoptosis. On the other hand, STAT6 may also exert tumor-suppressive effects in certain contexts, such as enhancing the body's immune surveillance of tumor cells by regulating immune cell functions. Therefore, in-depth research on the role of STAT6 in tumors will help develop new tumor therapeutic targets. This feature of “coexisting tumor-promoting and tumor-suppressive effects” suggests that STAT6-targeting strategies need to be differentially evaluated across different tumor types rather than adopting a uniform intervention direction.
VI. Research Progress and Future Directions of STAT6.
In recent years, with the continuous development of technologies such as gene editing, proteomics, and bioinformatics, many advances have been made in STAT6 research. For example, through gene knockout mouse models, the specific functions of STAT6 in the immune system and tissue development have been further clarified; using protein interaction network analysis, the complex regulatory relationships between STAT6 and other signaling pathway molecules have been revealed. However, many questions remain to be resolved. For example, the specific mechanisms of STAT6 in different cell types and physiological environments have not yet been fully clarified, and the relationship between its functions in disease and the cellular microenvironment still requires in-depth exploration. Future research directions may include: in-depth analysis of the fine regulatory mechanisms of the STAT6 signaling pathway and exploration of the cross-talk between STAT6 and other signaling pathways; development of small-molecule inhibitors or modulators specifically targeting STAT6 for the treatment of related diseases; and the use of technologies such as single-cell sequencing to study the role of STAT6 in cellular heterogeneity.
VII. Conclusion.
As an important cellular signal transduction factor, STAT6 plays multiple key roles in physiological and pathological processes through its multi-domain architecture composed of an N-terminal inhibitory domain, a DNA-binding domain, an SH2 domain, and a C-terminal transactivation domain; its complete activation cascade from receptor phosphorylation to SH2 docking and dimerization-dependent nuclear translocation; and its multifaceted functions in Th2 cell differentiation, B cell antibody class switching, macrophage activation, and epithelial cell adhesion regulation.
VIII. Common Questions and Product Information for STAT6 Binding Activity Detection
To facilitate the retrieval of evaluation schemes and product information for STAT6 interactions by researchers and drug development teams, this section answers common questions about STAT6 binding activity detection in a Q&A format and provides the product positioning and applicable scenarios of STAT6 GST Tag Protein, Human.
Q1: What methods are used to detect the binding activity of STAT6?
The functional core of STAT6 lies in the recognition of phosphorylated receptor peptides by its SH2 domain, followed by dimerization and DNA binding. Currently, in vitro methods for evaluating the interaction between STAT6 and phosphorylated receptor peptides, or for evaluating the ability of candidate molecules to block this interaction, mainly include enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR) and biolayer interferometry (BLI), and time-resolved fluorescence resonance energy transfer (TR-FRET). Among these, TR-FRET can complete binding reactions in homogeneous solution without coating and washing steps and can directly read the energy transfer signal between donor and acceptor, making it suitable for quantitative analysis and high-throughput screening of the binding activity between STAT6 and phosphorylated peptides.
The functional core of STAT6 lies in the recognition of phosphorylated receptor peptides by its SH2 domain, followed by dimerization and DNA binding. Currently, in vitro methods for evaluating the interaction between STAT6 and phosphorylated receptor peptides, or for evaluating the ability of candidate molecules to block this interaction, mainly include enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR) and biolayer interferometry (BLI), and time-resolved fluorescence resonance energy transfer (TR-FRET). Among these, TR-FRET can complete binding reactions in homogeneous solution without coating and washing steps and can directly read the energy transfer signal between donor and acceptor, making it suitable for quantitative analysis and high-throughput screening of the binding activity between STAT6 and phosphorylated peptides.
Q2: How does TR-FRET reflect the activity of STAT6 inhibitors?
In a TR-FRET system, donor and acceptor fluorophores are labeled on STAT6 protein and phosphorylated receptor peptides, respectively. When the two bind, the distance shortens and an energy transfer signal is generated. After adding small-molecule inhibitors or blocking antibodies targeting the STAT6 SH2 domain, the candidate molecules competitively occupy the binding interface of the SH2 domain, the complexes formed decrease, and the TR-FRET signal decreases with increasing inhibitor concentration; by plotting the signal inhibition rate against candidate molecule concentration, the half-maximal inhibitory concentration (IC50) can be fitted to compare inhibitory capacity and rank candidate molecules.
In a TR-FRET system, donor and acceptor fluorophores are labeled on STAT6 protein and phosphorylated receptor peptides, respectively. When the two bind, the distance shortens and an energy transfer signal is generated. After adding small-molecule inhibitors or blocking antibodies targeting the STAT6 SH2 domain, the candidate molecules competitively occupy the binding interface of the SH2 domain, the complexes formed decrease, and the TR-FRET signal decreases with increasing inhibitor concentration; by plotting the signal inhibition rate against candidate molecule concentration, the half-maximal inhibitory concentration (IC50) can be fitted to compare inhibitory capacity and rank candidate molecules.
Q3: What is STAT6 GST Tag Protein, Human?
STAT6 GST Tag Protein, Human (Catalog No. UA085028) is a human-derived STAT6 recombinant protein provided by UniOne (UA-Bio). It uses a GST tag, facilitating efficient purification by glutathione affinity chromatography and serving as a detection tag for assays such as ELISA, SPR, and TR-FRET. The expressed sequence is Trp123-Thr658 (Accession: P42226-1), covering key functional regions such as the SH2 domain. It is suitable for binding activity analysis of STAT6 with phosphorylated receptor peptides, mechanistic studies of SH2 domain-mediated dimerization, analysis of the DNA-binding properties of STAT6 with target gene promoter sequences, and in vitro screening and evaluation of small-molecule inhibitors and degraders targeting STAT6.
STAT6 GST Tag Protein, Human (Catalog No. UA085028) is a human-derived STAT6 recombinant protein provided by UniOne (UA-Bio). It uses a GST tag, facilitating efficient purification by glutathione affinity chromatography and serving as a detection tag for assays such as ELISA, SPR, and TR-FRET. The expressed sequence is Trp123-Thr658 (Accession: P42226-1), covering key functional regions such as the SH2 domain. It is suitable for binding activity analysis of STAT6 with phosphorylated receptor peptides, mechanistic studies of SH2 domain-mediated dimerization, analysis of the DNA-binding properties of STAT6 with target gene promoter sequences, and in vitro screening and evaluation of small-molecule inhibitors and degraders targeting STAT6.
Q4: What experimental scenarios is this product suitable for?
The main application scenarios of this product include: quantitative analysis of the binding activity between STAT6 and phosphorylated receptor peptides; in vitro screening and activity evaluation of small-molecule inhibitors or blocking antibodies targeting the STAT6 SH2 domain; determination and ranking of the half-maximal inhibitory concentration (IC50) of candidate molecules; verification of STAT6 dimerization mechanisms and DNA-binding properties; and parallel comparison of binding activity among different protein batches.
The main application scenarios of this product include: quantitative analysis of the binding activity between STAT6 and phosphorylated receptor peptides; in vitro screening and activity evaluation of small-molecule inhibitors or blocking antibodies targeting the STAT6 SH2 domain; determination and ranking of the half-maximal inhibitory concentration (IC50) of candidate molecules; verification of STAT6 dimerization mechanisms and DNA-binding properties; and parallel comparison of binding activity among different protein batches.
Q5: What are the characteristics of GST-tagged proteins compared with tag-free proteins?
The GST tag facilitates efficient purification by glutathione affinity chromatography, improving protein yield and purity; at the same time, GST itself can serve as a detection tag for recognition by anti-GST antibodies in assays such as ELISA and SPR, simplifying experimental procedures. For transcription factors such as STAT6 that mediate protein-protein interactions through the SH2 domain, the GST tag is located at the N-terminus and generally does not affect the binding activity of its SH2 domain to phosphorylated peptides, making it suitable for in vitro binding activity evaluation and inhibitor screening.
The GST tag facilitates efficient purification by glutathione affinity chromatography, improving protein yield and purity; at the same time, GST itself can serve as a detection tag for recognition by anti-GST antibodies in assays such as ELISA and SPR, simplifying experimental procedures. For transcription factors such as STAT6 that mediate protein-protein interactions through the SH2 domain, the GST tag is located at the N-terminus and generally does not affect the binding activity of its SH2 domain to phosphorylated peptides, making it suitable for in vitro binding activity evaluation and inhibitor screening.
Product Information at a Glance
| Product Name | STAT6 GST Tag Protein, Human (Catalog No.: UA085028) |
| Brand | UniOne (UA-Bio) |
| Molecular Aliases | STAT6C, STAT6B, interleukin-4 induced, IL-4-STAT, D12S1644 |
| Accession | P42226-1 |
| Expressed Sequence | Trp123-Thr658 with GST Tag at the N-Terminus |
| Expression System | E. coli |
| Molecular Weight | 70-100kDa (Reducing) |
| Purity | >80% by SDS-PAGE |
| Tag | GST Tag |
| Form | Liquid |
| Buffer System | 50mM Tris, 200mM NaCl, 1mM DTT, 1mM EDTA, 20% Glycerol, pH7.5 |
| Storage Conditions | Store at -80°C, stable for 12 months from the date of receipt, avoid repeated freeze-thaw cycles |
| Core Applications | Quantitative binding activity analysis, inhibitor screening and activity evaluation, IC50 determination, mechanism validation |
| Common Search Terms | STAT6 binding activity detection, STAT6 GST Tag Protein, STAT6 inhibitor screening, STAT6 IC50, STAT6 recombinant protein, UA085028, UniOne |
To conduct STAT6 binding activity detection or activity evaluation of inhibitors targeting STAT6, search the full product name “STAT6 GST Tag Protein, Human” or the catalog number “UA085028” in the UniOne (UA-Bio) Product Center to obtain product manuals, experimental protocols, and supporting reagent information.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose 
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Target proteins | membrane proteins | cytokines | enzymes | viral antigens | protein customization
Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161
Product Information
Link：
©2021-2026 all rights reserved UNIV Biotechnology Co.,Ltd.
Privacy Policy
网站备案号 苏ICP备2025207586号-2 浙公网安备33010202004867号
Business license (three certificates in one) Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.
